In re Fluoroquinolone Products Liability Litigation, 15-2642 (JRT). (2018)
Court: District Court, D. Minnesota
Number: infdco20180801c38
Visitors: 48
Filed: Jul. 30, 2018
Latest Update: Jul. 30, 2018
Summary: ORDER TO CONTINUE SEALING JOHN R. TUNHEIM , Chief District Judge . IT IS HEREBY ORDERED that the parties' Joint Motion for Continued Sealing [Docket No. 669] is GRANTED. Absent good cause and further Order of this Court, the Expert Report of Dr. Laura M. Plunkett, dated February 16, 2018 [Docket No. 616] and the Deposition Transcript of Dr. Laura M. Plunkett, dated April 25, 2018 [Docket No. 617] filed in connection with Defendants' Motion to Exclude Expert Testimony filed by Bayer Corp
Summary: ORDER TO CONTINUE SEALING JOHN R. TUNHEIM , Chief District Judge . IT IS HEREBY ORDERED that the parties' Joint Motion for Continued Sealing [Docket No. 669] is GRANTED. Absent good cause and further Order of this Court, the Expert Report of Dr. Laura M. Plunkett, dated February 16, 2018 [Docket No. 616] and the Deposition Transcript of Dr. Laura M. Plunkett, dated April 25, 2018 [Docket No. 617] filed in connection with Defendants' Motion to Exclude Expert Testimony filed by Bayer Corpo..
More
ORDER TO CONTINUE SEALING
JOHN R. TUNHEIM, Chief District Judge.
IT IS HEREBY ORDERED that the parties' Joint Motion for Continued Sealing [Docket No. 669] is GRANTED.
Absent good cause and further Order of this Court, the Expert Report of Dr. Laura M. Plunkett, dated February 16, 2018 [Docket No. 616] and the Deposition Transcript of Dr. Laura M. Plunkett, dated April 25, 2018 [Docket No. 617] filed in connection with Defendants' Motion to Exclude Expert Testimony filed by Bayer Corporation, Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG, and Merck & Co., Inc. [Docket No. 613] shall remained sealed for a period of one year, until July 30, 2019, to maintain the designated confidential status, pursuant to the April 27, 2016 Protective Order, of both documents.
Source: Leagle
